According to StockMKTNewz, Pfizer ($PFE) has secured licensing rights to a new Chinese cancer drug in a $1.25 billion deal, as reported by Semafor (Source: StockMKTNewz, May 20, 2025). This significant investment signals heightened biotech sector activity, which has historically spurred increased interest in blockchain-based solutions for drug development and supply chain transparency. Traders should monitor biotech token projects and related crypto assets for potential bullish sentiment following major pharmaceutical partnerships.